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Abstract
In an effort to develop octahedral metal complexes as chemotherapeutic and diagnostic agents
targeted to DNA, it is critical to optimize the properties of their cellular uptake. Appending D-
octaarginine has been found to improve both the uptake and nuclear localization efficiency of these
complexes, but the increased positive charge interferes with selective DNA binding and hence
activity. Herein, we evaluate the nuclear entry of a series of luminescent ruthenium peptide conjugates
of shorter sequence and lower charge. As is the case for the D-octaarginine conjugate (Ru-D-R8), the
tetrapeptide RrRK (where r = D-arginine) facilitates nuclear localization of the ruthenium complex
above a threshold concentration, though the threshold is higher for this conjugate (Ru-RrRK) than
for Ru-D-R8. Furthermore, appended fluorescein, which lowers the threshold concentration for Ru-
D-R8, does not improve nuclear entry of Ru-RrRK, indicating that fluorescein conjugation is not a
general strategy for modulating the distribution of cell-penetrating peptides. Similarly, the
concentration required for nuclear entry of Ru-RrRK is much higher than has been reported for a
thiazole orange RrRK conjugate, demonstrating the influence of payload on the efficiency of uptake
and localization of cell-penetrating peptides.
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1. Introduction
Peptide conjugation is a widely used and effective method for improving both cellular and
nuclear entry of a variety of cargo molecules.1–3 We have successfully delivered our rhodium
(III) 5,6-chrysenequinone diimine (chrysi) and ruthenium(II) dipyridophenazine (dppz)
complexes to the nucleus through covalent attachment of D-octaarginine.4,5 Without the
peptide, these compounds localize in the cytoplasm, as seen by microscopy studies on the
luminescent Ru(II) dppz complexes.6 Similarly, others have linked octaarginine to a ruthenium
bis(dipyridophenazine) complex, resulting in greatly increased cellular and nuclear
accumulation versus the parent complex.7 In general, ruthenium polypyridyl complexes exhibit
poor nuclear permeability without assistance of a targeting moiety, though there are exceptions.
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The chrysi complexes of rhodium(III) bind single-base mismatches in DNA,9,10 but the added
+8 charge imparted by octaarginine increases the nonspecific binding of the metal-peptide
conjugate, due to electrostatic association with the negatively charged DNA backbone.4 In
order to enhance the nuclear accumulation of our chrysi complexes of rhodium(III) without
significant impairment of their specificity for mismatches, we have now investigated
appending shorter peptides possessing less overall charge than octaarginine, but using
luminescent ruthenium analogues.
Studies by Kelley and coworkers have demonstrated the feasibility of using very short peptides
to target small molecules to the nucleus or mitochondria.11,12 Thiazole orange (TO) conjugated
to the tetrapeptide RrRK (r = D-arginine) accumulates primarily in the nucleus of HeLa cells,
whereas TO-FrFK localizes mainly in the mitochondria. Both conjugates are reported to cross
the plasma membrane with efficiencies approaching that of the longer Tat peptide
(RKKRRQRRR).11 Using RrRK as the nuclear targeting signal for metal complexes reduces
the positive charge added by the peptide in half compared to octaarginine, and thus should
reduce the amount of nonspecific DNA binding. Here, we use dppz complexes of Ru(II)
functionalized with short peptides, luminescent analogues of our rhodium complexes, to
evaluate the cellular uptake.
2. Results and discussion
2.1. Synthesis of the conjugates
A series of Ru(II) dipyridophenazine (dppz) conjugates were prepared by solid-phase coupling
of Ru(phen)(bpy′)(dppz)2+ to the N-terminal amine of the peptide. The dppz complexes of
ruthenium(II) serve as luminescent analogues of our chrysi complexes of rhodium(III).13 The
complexes bind duplex DNA by intercalation.14-16 In aqueous solution the luminescence is
quenched through hydrogen bonding, but when intercalated and protected from water, the
complex luminesces brightly.14,17 More generally, the ruthenium complexes function as light
switches for non-aqueous environments, luminescing only when bound to the hydrophobic
regions of membranes, nucleic acids, and other macromolecules. Furthermore, the ruthenium
complexes are stable in aqueous solution, making them useful cellular probes.
2.2 Cellular uptake of Ru-RrRK
We conjugated Ru(phen)(bpy′)(dppz)2+ to the nuclear targeting signal RrRK (r = D-arginine)
(Figure 1). HeLa cells incubated for 2 h with 5–20 μM Ru-RrRK show punctate cytoplasmic
luminescence, but no staining of the nucleus (Figure 2A, Table 1). Interestingly, increasing the
incubation time to 24 h does not change the subcellular localization of 20 μM Ru-RrRK. This
staining pattern is similar to that previously observed for the D-octaarginine conjugate of this
ruthenium complex (Ru-D-R8) at 5–10 μM.5 This distribution also implicates endocytosis, a
proposed mechanism of uptake for oligoarginine cell penetrating peptides,18 as the mode of
entry, though this remains to be confirmed by mechanistic studies. As expected, cellular uptake
of the peptide conjugate is enhanced compared to the unconjugated complex Ru
(phen)2dppz2+, as observed by direct comparison of the two complexes by confocal microscopy
following identical incubation conditions (10 μM, 2 h).
The same enhancement in cellular uptake for Ru-RrRK versus Ru(phen)2dppz2+ is seen by
flow cytometry analysis. Cells treated with Ru-RrRK have a 1.7-fold increase in mean
luminescence compared to those exposed to Ru(phen)2dppz2+ (Table 2). Given that the
luminescence of Ru-RrRK bound to DNA is inherently 61% of Ru(phen)2dppz2+ bound to
DNA, based upon titrations with calf thymus DNA, the uptake is enhanced 3-fold with the
appended short peptide. Significantly, however, the cellular uptake of Ru-RrRK is only ∼25%
that for Ru-D-R8 (Table 2). This observation is consistent with previous results showing that
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short oligoarginines are less effective at promoting the cellular entry of fluorescein than longer
ones.19 In fact, based upon cell luminescence, Ru-D-R8 shows a significantly higher level of
luminescent uptake in comparison to several ruthenium conjugates functionalized with slightly
shorter peptides (Table 2).
There is evidence in the literature that fluorescein-conjugated cell-penetrating peptides can
adhere to the cellular exterior,20 artificially increasing the apparent uptake when measured by
flow cytometry. Although trypsinization is recommended to reduce the membrane-bound
material, we did not use trypsin in these experiments, as it would preferentially cleave at the
L-amino acids, thus increasing the apparent amount of Ru-D-R8 cellular uptake versus our other
conjugates. Furthermore, the lack of defined staining of the cellular periphery in our confocal
microscopy experiments indicates that either our conjugates do not accumulate at the
membrane, or that the luminescence of such bound species is quenched.
At higher concentrations, the distribution of Ru-RrRK within cells changes, and the cell
population becomes heterogeneous. In addition to the punctate cytoplasmic structures, the
complex localizes in the nucleus in a small percentage of cells when incubated at 30–40 μM
(Figure 2B, Table 1). The fraction of cells with nuclear staining increases with concentration
of the complex. At 100 μM, the complex is located in the nucleus in 74% of cells (Figure 2C,
Table 1).
This population heterogeneity has been observed previously for fluorescein-nonaarginine21,
22 and for our ruthenium-octaarginine conjugate lacking fluorescein.5 A notable difference is
that Ru-RrRK requires a higher concentration (30 μM vs. 15 μM) to accumulate inside the
nucleus than Ru-D-R8, and a higher threshold (>40 μM vs. 20 μM) is necessary for the majority
of cells to exhibit nuclear staining. Thus RrRK is less effective at promoting nuclear uptake of
our ruthenium complex than D-octaarginine.
A shortened oligoarginine, Ru-tetraarginine (Ru-D-R4) was also examined, and it was found
to have similar cellular uptake characteristics to Ru-RrRK. When incubated at 20 μM for 2 h,
Ru-D-R4 is limited to punctate structures in the cytoplasm (Figure 3). At 30 μM, no cells had
nuclear staining, in contrast to Ru-RrRK which reached the nucleus in 7% of cells. These two
conjugates were synthesized with different C-termini, an amide for Ru-RrRK and a carboxylic
acid for Ru-D-R4. This could play a small role in their differences in cellular internalization,
however the amide- and carboxy-terminated versions of Ru-RrRK at 20 μM and 24 h show
similar uptake.
We also evaluated the cellular accumulation of Ru-RrRK in serum-free medium (Figure 4), to
allow comparison to the previously described experiments on the thiazole-orange conjugate
(TO-RrRK), which were performed in the absence of serum.11 Not surprisingly, Ru-RrRK
enters cells more readily under these conditions, and the concentration required for nuclear
staining is reduced. At only 30 μM complex for 2 h, half of the cells show nuclear staining
(Table 1). However, Ru-RrRK exhibits less efficient nuclear entry than TO-RrRK, which
localizes in the nucleus at a lower incubation concentration (5 μM for 1.5 h) in the same cell
line.11 Hence, the ability of RrRK to impart nuclear localization is affected by the nature of
the cargo, with the larger and more positively charged ruthenium complex being more difficult
to direct than thiazole orange.
In earlier experiments, we observed that attachment of fluorescein to Ru-D-R8 influences its
subcellular distribution, allowing the conjugate with fluorescein to enter the nucleus under
conditions for which the complex without fluorescein is excluded.5 Interestingly, an appended
fluorescein does not have the same effect on Ru-RrRK; instead, cellular uptake is impaired by
the dye. At concentrations up to 30 μM and 2 h incubation, only punctate cytoplasmic
luminescence is seen (Figure 5), whereas the conjugate lacking fluorescein localizes in the
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nucleus in 7% of cells under these conditions (Table 1). The lack of benefit from fluorescein
could be due the stronger relative effect of its negative charge on this shorter peptide. The
fluorescein-tagged peptide also contains a carboxylic acid terminus, rather than the amide,
which adds another negative charge. With reduced positive charge, the conjugate is less able
to use the membrane potential as a driving force for entry; membrane potential has been shown
to be an important factor in the cellular uptake of guanidinium-rich peptides.23
2.3 Effect of sequence variations on short peptides
It is known in the literature that charge is not the sole determinant in the uptake of cell-
penetrating peptides; oligoarginines enter cells much more effectively than oligolysines.21 To
confirm this for our system, we examined the cellular entry of Ru-KKKK. We also synthesized
Ru-SrSr, which has even less total charge, but still contains two arginines. For Ru-KKKK and
Ru-SrSr, only faint luminescence in the cytoplasm was observed after incubation at 40 μM for
2 h. Increasing the incubation concentration and time (100 μM, 4 h) leads to brighter, punctate
cytoplasmic staining, and a small percentage of cells (17% for Ru-KKKK and 5% for Ru-SrSr)
exhibit additional nuclear staining (Figure 6). Ru-KKKK luminescence in the cells is a little
more intense than Ru-SrSr, indicating that its increased positive charge gives a small advantage
over the two arginines of Ru-SrSr. As expected, both Ru-KKKK and Ru-SrSr are poorly
internalized compared to Ru-RrRK.
Two longer peptides that correspond to known nuclear localization signals (NLSs) were also
studied, PKKKRKV and KSKKQK.24 NLSs promote active transport through the nuclear pore
complex, but the use of an NLS does not guarantee nuclear uptake. They must reach the cytosol
in order to access the nuclear import machinery. If the NLS conjugates enter by endocytosis,
they could become trapped in endosomes. However, a cobaltocenium cation has previously
been successfully targeted to the nucleus using PKKKRKV.25 Furthermore, the chosen
peptides possess less overall charge than octaarginine, and thus are suitable candidates in our
efforts to reduce the nonspecific binding of our metal-peptide conjugates to DNA.
Treatment of HeLa cells with 10 μM Ru-PKKKRKV or Ru-KSKKQK for 2 h reveals only
faint punctate luminescence in the cytoplasm and no nuclear staining. Increasing the incubation
time to 19 h provides the same result (Figure 7). Hence, neither NLS is more effective at
promoting nuclear localization of our ruthenium complex than D-octaarginine, which is also
excluded from the nucleus at 10 μM. In fact, analysis by flow cytometry reveals that cellular
accumulation is even less than that for Ru-RrRK, despite having similar charge (Table 2).
Presumably, at higher concentrations, these Ru-NLS conjugates will accumulate in the nucleus,
similar to Ru-RrRK.
3. Conclusion
The large positive charge of octaarginine-metal complex conjugates both improves uptake and
interferes with selective DNA binding. To resolve this issue, we studied our luminescent
ruthenium complex tethered to the shorter and less charged peptide RrRK, which efficiently
addresses the organic fluorophore thiazole orange to the nucleus.11 We found that this peptide
was far less capable for delivery of the ruthenium complex than it was for thiazole orange,
illustrating again the importance of payload to the accumulation and distribution of cell-
penetrating peptides. Furthermore, the low positive charge of short peptide conjugates
abrogates the benefits from fluorescein attachment that we previously observed for Ru-
octaarginine. Nevertheless, RrRK conjugation increases cellular uptake as compared to
analogous unconjugated complexes, and, above a threshold concentration of 30 μM, this
peptide targets the ruthenium complex to the nucleus.
Puckett and Barton Page 4














4.1. Materials and instrumentation
Media, cell culture supplements, Hanks' balanced salt solution, and TO-PRO®-3 iodide were
purchased from Invitrogen (Carlsbad, CA).
MALDI measurements were performed on an Applied Biosystems Voyager 6215. Absorption
spectra were recorded on a Beckman DU 7400 spectrophotometer. HPLC was performed on
an HP1100 system equipped with a diode array detector using a Vydac C18 reversed-phase
semipreparative column.
4.2. Synthesis of Ru-peptide conjugates
Peptides, protected and resin-bound, were purchased from Anaspec (Fremont, CA). Rink resin
was used to produce amide-terminated peptides. Ru(phen)(bpy′)(dppz)2+ was coupled to the
peptide in an analogous manner to that previously described (where phen = 1,10-
phenanthroline, bpy′ = 4-(3-carboxypropyl)-4′-methyl-2,2′-bipyridine, and dppz = dipyrido
[3,2-a:2′,3′-c]phenazine).4,26 Ru-D-R8, which we earlier examined,5 was made with a C-
terminal carboxylic acid. The Ru-RrRK conjugate was synthesized in both the amide- and
carboxy-terminated versions for comparison; unless otherwise noted, Ru-RrRK refers to the
amide-terminated form. A fluorescein-labeled version, Ru-RrRK-fluor, was synthesized by
methods analogous to those reported for Ru-D-R8 tagged with fluorescein (Ru-D-R8-fluor).
5 As with Ru-D-R8-fluor, fluorescein was appended off a C-terminal lysine, and the peptide
contains a carboxylic acid at its C-terminus. Ru-KSKKQK and Ru-PKKKRKV were
synthesized with C-terminal amides, and Ru-D-R4, Ru-KKKK and Ru-SrSr have the C-
terminal carboxylic acid. Ruthenium-peptide conjugates were purified by reversed-phase
HPLC using a water (0.1% trifluoroacetic acid)/acetonitrile gradient and characterized by
MALDI-TOF mass spectrometry; Ru-RrRK: 1416.3 m/z (M+) obsd, 1415.6 m/z (M+) calcd,
Ru-RrRK-COOH: 1417.6 m/z (M+) obsd, 1416.6 m/z (M+) calcd, Ru-RrRK-fluor: 1935.6 m/
z (M+) obsd, 1933.7 m/z (M+) calcd, Ru-D-R4: 1443.6 m/z (M+) obsd, 1444.6 m/z (M+) calcd,
Ru-KKKK: 1333.0 m/z (M+) obsd, 1332.6 m/z (M+) calcd, Ru-SrSr: 1307.1 m/z (M+) obsd,
1306.4 m/z (M+) calcd, Ru-PKKKRKV: 1683.8 m/z (M+) obsd, 1683.8 m/z (M+) calcd, Ru-
KSKKQK: 1546.6 m/z (M+) obsd, 1546.7 m/z (M+) calcd. All conjugates employed in this
study were used as their trifluoroacetate salts. Concentrations were determined by the
absorption of Ru(phen)(bpy′)(dppz)2+; for Ru-RrRK-fluor, 361 nm, which is not obscured by
fluorescein, was used (ε440= 19,000 M-1 cm-1; ε361= 19,469 M-1 cm-1). Ru(phen)2dppz2+, used
for comparison to the conjugates in uptake studies, was synthesized as described previously;
6 ε440 = 21,100 M-1 cm-1.27
4.3. Cell culture
HeLa cells (ATCC, CCL-2) were maintained in minimal essential medium alpha with 10%
fetal bovine serum (FBS), 100 units/mL penicillin, and 100 μg/mL streptomycin. Cells were
grown in tissue culture flasks at 37 °C under 5% CO2 atmosphere.
4.4. Confocal Microscopy
HeLa were seeded using 4000 cells in wells of a glass-bottom 96-well plate (Whatman Inc.)
and allowed to adhere overnight. The complexes were incubated with HeLa cells at 37 °C in
complete medium (minimal essential medium alpha with 10% fetal bovine serum) or medium
without serum, as indicated. Imaging was performed using a 63x/1.4 oil immersion objective
on a Zeiss LSM 510 or a Zeiss LSM 5 Exciter inverted microscope. The optical slice was set
to 1.1 μm. Ru-peptide conjugates were excited at 488 nm, with emission observed at 560+ nm.
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For Ru-RrRK-fluor, the emission was collected as the combined emission of Ru and fluorescein
(505+ nm), both of which are excited at 488 nm.
4.5. Flow cytometry
Cells were detached from culture with EDTA (0.48 mM in phosphate-buffered saline) and
incubated at 1×106 cells/mL with 10 μM ruthenium complex in Hanks' balanced salt solution
(HBSS) supplemented with 2.5 mg/mL bovine serum albumin fraction V (BSAV) at 37 °C for
2 h, then rinsed with buffer and placed on ice. TO-PRO-3 was added at 1 μM immediately
prior to flow cytometry analysis to stain dead cells. The fluorescence of ∼20,000 cells was
measured using a BD FACS Aria at the Caltech Flow Cytometry Facility. Ruthenium
complexes were excited at 488 nm, with emission observed at 600–620 nm. TO-PRO-3 was
excited at 633 nm, with emission observed at 650–670nm. Cells exhibiting TO-PRO-3
fluorescence were excluded from the data analysis.
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Structures of Ru-RrRK conjugates.
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Subcellular distribution of Ru-RrRK. HeLa were incubated with (A) 20, (B) 40, or (C) 100
μM Ru-RrRK in complete medium for 2 h. At 20 μM, only punctate staining of the cytoplasm
is present. At higher concentrations, some cells show additional nuclear staining. Scale bars
are 10 μm.
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Subcellular distribution of Ru-D-R4. The structure of the conjugate is shown in (A). HeLa cells
were incubated with (B) 20 or (C) 30 μM Ru-D-R4 in complete medium for 2 h. Punctate
staining of the cytoplasm is observed. Scale bars are 10 μm.
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Subcellular distribution of Ru-RrRK in serum-free medium. HeLa were incubated with (A) 20
or (B) 40 μM Ru-RrRK in for 2 h. At 20 μM in medium without serum, the most cells show
only punctate cytoplasmic staining, while at 40 μM, the majority of cells exhibit additional
nuclear labeling. Scale bars are 10 μm.
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Subcellular distribution of Ru-RrRK-fluor. HeLa were incubated with 30 μM Ru-RrRK-fluor
for 2 h in complete medium. Punctate staining of the cytoplasm is observed. Scale bar is 10
μm.
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Subcellular distribution of Ru-KKKK and Ru-SrSr. HeLa cells were incubated for 4 h with
100 μM (A) Ru-KKKK or (B) Ru-SrSr in complete medium. Structures of the conjugates are
shown at left. The cells shown display punctate staining of the cytoplasm. Scale bars are 10
μm.
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Subcellular distribution of Ru-NLS conjugates. HeLa cells were incubated for 19 h with 10
μM (A) Ru-KSKKQK or (B) Ru-PKKKRKV in complete medium. Structures of the conjugates
are shown at left. Punctate staining of the cytoplasm is observed. Scale bars are 10 μm.
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Table 1
Percentage of cells with nuclear staining by Ru-RrRKa







HeLa cells were incubated with Ru conjugate for 2 h at 37 °C in medium +/- serum, then rinsed with HBSS and analyzed by confocal microscopy.
Dead cells were excluded by their morphology. Data not determined are indicated by n.d.
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Table 2
Cellular uptake of ruthenium conjugates assayed by flow cytometry
complex mean luminescence (a.u.)a
Ru(phen)2dppz2+ 79 ± 17
Ru-D-R8 328 ± 11
Ru-RrRK 133 ± 7
Ru-PKKKRKV 86 ± 4
Ru-KSKKQK 73 ± 8
a
HeLa cells were incubated with 10 μM ruthenium conjugate for 2 h at 37 °C. Ruthenium complexes were excited at 488 nm, with emission observed
at 600–620 nm. The mean luminescence intensity of cells not treated with complex is 20. Each data point is the mean ± the standard deviation of three
samples.
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